Pfizer is certainly not giving up on its acquisition attempt for AZ, and they begun mobilizing the communication department to get the word out on why this deal is such a good thing. Over the weekend, CEO Ian Read put out a series of videos explaining the thinking behind and benefits of the acquisition. He stressed the compan's commitment to research and the complementary nature of the AZ pipeline with that of Pfizer. See Bloomberg.
Today, he'll get a further chance to lay out Pfizer's case when he and AZ CEO Pascal Soriot will both appear before the parliament to explain their positions. Read can expect to be grilled on Pfizer's commitment toward the AZ Cambridge R&D center that is going up, to R&D staffing in the UK generally, and to Pfizer's decision a few years ago to cut back on 1700+ jobs at its Sandwich facility. You can expect members of UK parliament to be assertive and to try to pin commitments on Pfizer going forwad if the deal is successful. See Pharma Times 1 & 2.
Pfizer's R&D chief, Mikael Dolsten, is also talking to the public airwaves to explain why the Pfizer-AZ deal is such a good thing from the R&D perspective. He says Pfizer has a long history of acquiring companies and blending them into something new and better. He also says that AZ's pipeline is extremely well matched to pair with Pfizer's -- particularly in such disease areas as lung cancer. He says the deal is a "really great fit". We'll see shant we. See First Word Pharma.
Posted by Bruce Lehr May 12th 2014.